<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956601</url>
  </required_header>
  <id_info>
    <org_study_id>ECART001</org_study_id>
    <nct_id>NCT04956601</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy in Patients With Early Endometrial Cancer</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Trial of Adjuvant Radiotherapy in Patients With Early Endometrial Cancer Based on Moderate Risk Molecules Classification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when&#xD;
      compared to pelvic external beam radiotherapy in patients with early endometrial cancer based&#xD;
      on moderate risk molecules classification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed the study and potential risk，all patients giving written informed&#xD;
      consent will be undergo a 1-week screening period determine eligibility for study entry. At&#xD;
      week 0, patients who meet the eligibility will be randomized in a 1:1 ratio to vaginal&#xD;
      brachytherapy or pelvic external beam radiotherapy. After treatment, patients were followed&#xD;
      up regularly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">August 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>5-year</time_frame>
    <description>disease-free survival from being received treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure mode</measure>
    <time_frame>5-year</time_frame>
    <description>vaginal recurrences; pelvic recurrence; distant metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5-year</time_frame>
    <description>Overall survival from being received treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>5-year</time_frame>
    <description>from being received treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Pathology</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>VBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>vaginal brachytherapy/pelvic external beam radiotherapy</intervention_name>
    <description>high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy</description>
    <arm_group_label>EBRT</arm_group_label>
    <arm_group_label>VBT</arm_group_label>
    <other_name>Pelvic external beam radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were&#xD;
             microsatellite instability type and low copy type;&#xD;
&#xD;
          2. Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space&#xD;
             invasion;&#xD;
&#xD;
          3. Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node&#xD;
             sampling and para-aortic lymph node sampling are optional;&#xD;
&#xD;
          4. ECOG score is 0-2;&#xD;
&#xD;
          5. The interval time between surgery and radiotherapy is no more than 8 weeks;&#xD;
&#xD;
          6. The routine blood examination was normal;&#xD;
&#xD;
          7. Compliance is good and informed consent is voluntarily signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patients receive chemotherapy;&#xD;
&#xD;
          2. History of previous malignant disease;&#xD;
&#xD;
          3. Previous diagnosis of Crohn's disease or ulcerative colitis.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junjie Wang</last_name>
    <phone>861082265920</phone>
    <email>junjiewang_edu@sina.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University 3rd Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijng</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Junjie Wang</investigator_full_name>
    <investigator_title>Peking University Third Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

